Fever-Tree has recorded a 2% year-on-year increase in its revenue, totalling £375.3m in 2025, in what the firm described as a "pivotal" year.

The drinks company said the figure reflects improving momentum across regions and further market share gains. It added that 45% of its group revenue was generated beyond tonic, as it broadened its relevance across a “wider range of adult socialising occasions”.

Fever-Tree stated that it continued strong US brand momentum following its partnership with Molson Coors, which is set to establish a “scalable platform” for accelerated growth in 2026.

However, its UK revenue dropped by 2% year-on-year, although its performance improved in the second half, driven by a strong off-trade performance.

In 2025, Fever-Tree’s earnings dropped by 16% to £42.4m, which included a post-period end adjustment to provide for a potential incremental £2.8m charge relating to the UK EPR levy. Excluding this provision, its earnings reached £45.2m, which was in line with previous guidance.

The update comes after the drinks firm completed a £100m share buyback, which was funded b “strong operational cash flow, working capital efficiencies and transaction proceeds from the Molson Coors share issue”.

It has also announced a further £30m share buyback scheme, which is currently in progress.

In its outlook, Fever-Tree said it has entered the year from a “position of strength” and notwithstanding the current uncertain geopolitical outlook, its expectations remain unchanged and in line with market guidance.

Following its trading update, shares in Fever-Tree increased by almost 8%.

Chief executive officer and co-founder at Fever-Tree, Tim Warrilow, concluded: "[Last year] was a pivotal year for Fever-Tree. The strategic partnership with Molson Coors in the US creates a significant opportunity to take Fever-Tree to the next level in our largest growth market. The transition has progressed well, and it has been particularly encouraging to see that underlying brand momentum has remained strong throughout.

"Across our markets, the long-term trends shaping adult socialising, namely premiumisation, moderation and longer, lighter serves, continue to play directly to our strengths. Fever-Tree is increasingly enjoyed as the world's leading premium mixer, but also as a premium soft drink. Products beyond tonic now represent 45% of group revenue, a clear sign that our diversification strategy is resonating with consumers.

"As we enter 2026, Fever-Tree does so from a position of strength. We have a premium brand with unmatched credentials, an ever-growing market leadership position, upweighted marketing plans, a broader and more relevant portfolio, and scalable platforms in place across our priority markets."

---